Supernus Pharmaceuticals (SUPN) EBT (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has reported EBT for 16 consecutive years, with -$57.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 445.84% year-over-year to -$57.6 million in Q2 2026; TTM through Jun 2026 was -$100.8 million, a 222.74% decrease from a year earlier, with the FY2025 full-year figure at -$49.0 million, down 150.1% from the prior year.
• EBT was -$57.6 million for Q2 2026 at Supernus Pharmaceuticals, down from -$1.9 million in the prior quarter.
• Over five years, EBT peaked at $44.9 million in Q3 2024 and troughed at -$58.0 million in Q3 2025.
• A 5-year average of $3.2 million and a median of $9.0 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 2564.85% in 2024 and slumped 2499.59% in 2025, its largest moves.
• Over 5 years, EBT stood at $35.1 million in 2022, then sank by 97.18% to $990000.0 in 2023, then jumped by 2564.85% to $26.4 million in 2024, then plunged by 107.25% to -$1.9 million in 2025, then plunged by 2911.91% to -$57.6 million in 2026.
• The last three EBT figures came in at -$57.6 million (Q2 2026), -$1.9 million (Q4 2025), and -$58.0 million (Q3 2025), per Business Quant data.